免疫球蛋白超家族成员8通过抑制β-连环蛋白降解维持髓系白血病干细胞
研究利用条件性敲除模型发现,Igsf8缺失不影响稳态造血,但显著改善小鼠髓系白血病模型生存,并通过增强凋亡和β-连环蛋白降解耗竭白血病干细胞;IGSF8抑制可阻断白血病干细胞集落形成并改善异种移植模型受体生存。
要点
- Igsf8缺失不影响稳态造血,但显著改善小鼠髓系白血病模型生存。
- Igsf8缺失通过增强凋亡和β-连环蛋白降解显著耗竭白血病干细胞。
- IGSF8抑制阻断白血病干细胞集落形成并改善异种移植模型受体生存。
核心结论
- Igsf8是髓系白血病的关键调控因子,靶向IGSF8可能成为髓系白血病的新治疗途径。
研究设计与样本
- 研究主要使用条件性敲除模型,探究免疫球蛋白超家族成员8(Igsf8,又称EWI-2、PGRL、CD316)对正常和恶性造血干细胞的作用。
主要发现
- Igsf8缺失不影响稳态造血,但显著改善小鼠髓系白血病模型的生存。
- Igsf8缺失通过增强凋亡和β-连环蛋白降解显著耗竭白血病干细胞(LSCs)。
- LSCs中β-连环蛋白的激活依赖Igsf8,Igsf8促进FZD4与其共受体LRP6在Igsf8存在时的结合。
- IGSF8抑制阻断LSCs的集落形成能力,并改善髓系白血病异种移植模型受体的生存。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The identification of characteristic differences between cancer stem cells and their normal counterparts remains a key challenge for cancer treatment. Here, we investigated the role of immunoglobulin superfamily member 8 (Igsf8, also known as EWI-2, PGRL, and CD316) on normal and malignant hematopoietic stem cells, mainly using the conditional knockout model. Deletion of Igsf8 did not affect steady state hematopoiesis, but it led to a significant improvement of survival in mouse myeloid leukemia models. Deletion of Igsf8 significantly depletes leukemia stem cells (LSCs) through enhanced apoptosis and β-catenin degradation. At a molecular level, we found that activation of β-catenin in LSCs depends on Igsf8, which promotes the association of FZD4 with its co-receptor LRP6 in the presence of Igsf8. Similarly, IGSF8 inhibition blocks the colony-forming ability of LSCs and improves the survival of recipients in xenograft models of myeloid leukemia. Collectively, these data indicate strong genetic evidence identifying Igsf8 as a key regulator of myeloid leukemia and the possibility that targeting IGSF8 may serve as a new therapeutic approach against myeloid leukemia.
引用
- Jimbo K, Nakajima-Takagi Y, Ito T, et al. Immunoglobulin superfamily member 8 maintains myeloid leukemia stem cells through inhibition of β-catenin degradation. Leukemia. 2022. PMID: 35418614. doi:10.1038/s41375-022-01564-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。